Arno Therapeutics, Inc. (OTCPK: ARNI)
Health Care · Biotechnology · US
$—
— today · — 1Y
Arno Therapeutics, Inc. (OTCPK: ARNI) operates in the Biotechnology industry within the Health Care sector. The company is valued at $4.93K and employs 4 people.
trading between 0.00 and 0.00.
Tweenvest scores Arno Therapeutics, Inc. across four factors: quality 21/100. Its strongest factor is quality.
ARNI price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $4.93K
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.38
- Dividend yield
- —
- Beta (5Y)
- -30.33
- 52-week high
- $0.00
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 49.35M
- Employees
- 4
- Next earnings
- —
About Arno Therapeutics, Inc.
Arno Therapeutics, Inc., headquartered in Flemington, New Jersey, operates as a biopharmaceutical enterprise focused on discovering and advancing treatments for cancer and other severe health conditions. The company's developmental portfolio includes several key compounds: Onapristone, a type 1 anti-progestin hormone blocker, is currently undergoing Phase I/II clinical trials. This therapeutic is being investigated for its efficacy in treating various solid tumors, such as breast and endometrial cancers in post-menopausal women, and advanced castration-resistant prostate cancer in men. AR-12, an orally administered cancer therapy, has successfully completed Phase I clinical studies for solid tumors and hematological malignancies. Additionally, it is in pre-clinical development for potential applications against a range of microbial targets. AR-42, another innovative oral cancer treatment, is involved in a Phase I investigator-initiated clinical study, targeting both hematological malignancies and solid tumors. To support its research and development efforts, Arno Therapeutics has established licensing agreements with Invivis Pharmaceuticals, Inc., the Regents of the University of Minnesota, and the Ohio State University Innovation Foundation. The company also holds a co-development partnership with Leica Biosystems Newcastle Ltd.
- ISIN
- US0425642032
- Founded
- 2005
- Listed since
- Jun 11, 2008
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $261.53 | -1.60% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $439.02 | -0.73% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $147.48 | -0.87% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $547.02 | -1.05% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $825.08 | -1.02% |
| argenx SEENXTBR: ARGX | $64.17B | €895.40 | +1.84% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $150.71 | -5.11% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.